Scholar Rock gains as muscle disorder drug gets priority US review

Scholar Rock's shares SRRK.O up 3.4% premarket

Co says U.S. FDA accepts SRRK's drug, apitegromab, for priority review with a decision expected by Sept 22; EU's medicines regulator has also accepted drug for review

Co's drug treats spinal muscular atrophy, which stops production of a protein necessary for neuromuscular development and leaves children too weak to walk, talk and swallow

In a late-stage study, patients given apitegromab saw better improvement in motor function than those given a placebo

As of last close, SRRK up nearly 17% so far this year